Reports 2022 revenue $386K, consensus $330K. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025. "2022 was an important year for demonstrating the benefits onvansertib could bring to patients with KRAS-mutated mCRC, an area where no targeted therapies are currently approved. The results of our Phase 1b/2 trial in KRAS-mutated mCRC continue to show onvansertib plus standard-of-care was well-tolerated and outperformed historical control trials on key endpoints including the durability of response. Furthermore, we observed an unexpectedly high objective response rate and progression-free survival in the bevacizumab-naive subgroup of patients which will be evaluated in the ongoing ONSEMBLE trial," said CEO Mark Erlander. "Looking forward, this will be an important year for advancing our ONSEMBLE randomized Phase 2 trial and generating additional safety and efficacy signals from our other company-sponsored and investigator-initiated clinical programs…We are confident we can fund our onvansertib clinical programs into 2025, and we believe our clinical data supports our approach to leveraging PLK1 inhibition to address current gaps in cancer therapies and make an important contribution to oncology patient care."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRDF:
